All News

Article

EULAR 2025 – Day 3 Report

Jack Cush, MD Jun 13, 2025

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.

APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3

https://x.com/DrMiniDey/status/1933831530633162911/photo/1

#GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN

Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT

Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z

https://x.com/AdelaCastro222/status/1933834754052247622/photo/1

ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu

#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ

https://x.com/Yuz6Yusof/status/1933839342335873433/photo/1

LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA) more good efficacy data, no rapidly progressive OA safety signal. For us clinicians: impressive impact size, esp relative to alternatives. Finally, something that works?? #EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv

https://x.com/drdavidliew/status/1933847024580862235/photo/1

In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ

https://x.com/synovialjoints/status/1933597498548904144/photo/1

#Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1

https://x.com/Janetbirdope/status/1933606087351218244/photo/1

How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg

https://x.com/Janetbirdope/status/1933609025469632983/photo/1

#TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90 400mg/d all in low GFR toxic 200mg/d 25% in low GFR toxic 6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE

1/3 of #ERA pts poor Outcomes despite controlled disease! 2 #RCT with T2T in early #RA #CARERA 👇 persistent impact ⬆️TJC, comorbidities ⬇️SJC, CRP, global, HAQ, F>M ⬆️disease durat’n ▶️ ⬆️ b/tsDMARDs despite =diseaese vs others ?overRx OP0330 #EULAR2025 @RheumNow @eular_org

Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3

Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/wmTnFbFcum

https://buff.ly/jOLBrQY

Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV

PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity

Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj

In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m

https://x.com/synovialjoints/status/1933527987514646938/photo/1

#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7

https://x.com/Yuz6Yusof/status/1933532364443168839/photo/1

Topics

All News

EULAR 2025 – Day 3 Report

Do you get our email newsletter?